Neoleukin Therapeutics Inc (NAS:NLTX)

$ 3.49 0 (0%) Market Cap: 8.20 Mil Enterprise Value: -35.02 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 22/100

Capricor Therapeutics Inc Phase 3 Hope 3 Program Update Transcript
Sep 29, 2023
Q2 2023 Capricor Therapeutics Inc Earnings Call Transcript
Aug 07, 2023

$13 (-0.91%)

Earnings
Q1 2023 Capricor Therapeutics Inc Earnings Call Transcript
May 11, 2023

$17.63 (-1.57%)

Earnings
Q4 2022 Capricor Therapeutics Inc Earnings Call Transcript
Mar 15, 2023

$12.4 (-0.08%)

Earnings
Capricor Therapeutics Inc To Present 18-Month Data Results From Ongoing HOPE-2 Open Label Extension Transcript
Jan 25, 2023
Q3 2022 Capricor Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$10.45 (+2.47%)

Earnings
Capricor Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Q2 2022 Capricor Therapeutics Inc Earnings Call Transcript
Aug 10, 2022

$19.67 (+0.79%)

Earnings
Capricor Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
May 25, 2022
Q1 2022 Capricor Therapeutics Inc Earnings Call Transcript
May 10, 2022

$23 (+0.88%)

Earnings
Q4 2021 Capricor Therapeutics Inc Earnings & Recent Corporate Update Call Transcript
Mar 10, 2022
Capricor Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 Capricor Therapeutics Inc Earnings Call Transcript
Aug 12, 2021

$139.8 (-0.99%)

Earnings
Q1 2021 Capricor Therapeutics Inc Earnings Call Transcript
May 13, 2021

$207.8 (-2.72%)

Earnings
Q4 2020 Capricor Therapeutics Inc Earnings Call Transcript
Mar 11, 2021

$250.8 (+7.09%)

Earnings
Q3 2020 Capricor Therapeutics Inc Earnings Call Transcript
Nov 12, 2020

$250 (+5.13%)

Earnings
Capricor Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 12, 2020
Capricor Therapeutics Inc Overview of CAP-1002 in Patients with Duchenne Muscular Dystrophy Transcript
Sep 02, 2020
Q2 2020 Capricor Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

$213.8 (+0.66%)

Earnings
Q1 2020 Capricor Therapeutics Inc Earnings Call Transcript
May 14, 2020

$260 (-0.76%)

Earnings
Capricor Therapeutics Inc to Discuss the Top-Line Results of the HOPE-2 Study - Call Transcript
May 13, 2020
Capricor Therapeutics Inc to Host Key Opinion Leader (KOL) Call on CAP-1002 Transcript
Apr 15, 2020
Capricor Therapeutics Inc to Host Key Opinion Leader (KOL) Call Transcript
Mar 26, 2020
Q4 2019 Capricor Therapeutics Inc Earnings Call Transcript
Mar 18, 2020

$122.4 (-12.94%)

Earnings

Q2 2022 Capricor Therapeutics Inc Earnings Call Transcript

Aug 10, 2022 / 08:30PM GMT

Release Date Price: $19.67 (+0.79%)

Transcript 10-Q8-K

Operator

Good day, and welcome to the Capricor Therapeutics second-quarter 2022 earnings call. Today's conference is being recorded. At this time, I'd like to turn the conference over to AJ Bergmann, CFO. Please go ahead, sir.

AJ Bergmann

Capricor Therapeutics, Inc. - CFO

Thank you and good afternoon. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates; our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies; our plans to present or report additional data; our plans regarding regulatory filings; potential regulatory developments involving our product candidates; central milestone payments; and our possible uses of existing cash and investment resources.

These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.